HTA Method Shifts & Digital Evidence

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: Asia-Pacific HTA method evolution, emerging markets RWE hurdles, digital therapeutics evidence gaps, and orphan drug RWE complexities. Let's get into it.

SaraStarting with Asia-Pacific. HTA bodies are increasingly adopting hybrid methodologies blending cost-effectiveness with broader value frameworks. But Marcus, this creates inconsistent comparability across jurisdictions. How do companies navigate this fragmentation without diluting their evidence strategy?

MarcusThe frameworks aren't inherently fragmented—they're adapting to local healthcare priorities. Companies must align with regional value elements, not force-fit Western models. The evidence requirements are clear; adaptability is the commercial imperative.

SaraClear? Japan's new cost-effectiveness threshold adjustments and Thailand's health technology prioritization criteria introduce significant unpredictability. Relying on "broader value" frameworks risks subjective assessments. Where's the methodological rigor?

MarcusRigor lies in transparency. Stakeholders define value; HEOR quantifies it. The alternative—rigid thresholds—fails in diverse health systems. Evidence must reflect context, not override it.

SaraShifting to emerging markets. RWE integration is accelerating but faces infrastructure and data quality barriers. Marcus, is this a technical hurdle or a fundamental evidence credibility crisis for HTA submissions?

MarcusInfrastructure is solvable. The real issue is regulatory acceptance of RWE endpoints. HTA bodies need standardized frameworks, not just data pipelines. Evidence credibility stems from methodology, not data volume.

SaraFrameworks exist, but implementation lags. Brazil's ANVISA and South Africa's SAHTA lack clear RWE guidelines for pivotal decisions. Without regulatory clarity, companies invest in RWE that HTA bodies dismiss as supplementary. That's not integration—it's marginalization.

MarcusSupplementary evidence still shapes assessments. The absence of formal guidelines doesn't negate RWE utility; it demands stronger methodological justification. Companies must lead with evidence robustness, not just data availability.

SaraDigital therapeutics now face HTA assessment. Marcus, how do we measure clinical utility when endpoints are behavioral and outcomes are long-term? Current HTA models are ill-equipped.

MarcusBehavioral endpoints require validated PROs and digital biomarkers. The evidence challenge isn't HTA methodology—it's defining meaningful endpoints. Companies must develop consensus-driven endpoints, not assume HTA systems will adapt.

SaraAdaptation is necessary. The UK's NICE and Germany's G-BA lack standardized digital health evaluation pathways. Without clear criteria, digital therapeutics face arbitrary barriers. This stifles innovation in areas with high unmet need.

MarcusArbitrary barriers exist for all novel therapies. Digital therapeutics aren't uniquely disadvantaged; they require the same evidence rigor as any new modality. The solution lies in endpoint development, not HTA reform.

SaraFinally, orphan drugs. RWE requirements are intensifying, but real-world data for rare diseases is scarce. Marcus, is this feasible or an unrealistic burden for small biotechs?

MarcusFeasible through federated networks. DARWIN EU and similar platforms demonstrate that data sharing can overcome scarcity. The burden isn't on companies—it's on collaborative infrastructure.

SaraCollaboration requires trust. Data sharing across borders for ultra-rare conditions faces privacy and regulatory hurdles. Companies can't build networks alone; HTA bodies must facilitate frameworks. Without that, RWE requirements remain aspirational, not operational.

MarcusOperationalization is already underway. HTA bodies are engaging with federated models. The burden shifts to companies to demonstrate data utility within emerging frameworks.

SaraOperationalization is uneven. Some regions embrace federated approaches; others impose restrictive data sovereignty rules. This inconsistency creates unequal access to RWE tools. Equity demands harmonization, not experimentation.

MarcusEquity demands evidence, not uniformity. Contextual relevance outweighs procedural alignment. Companies must navigate diversity, not demand homogeneity.

SaraContextual relevance requires methodological flexibility. HTA bodies must evolve their assessment criteria to reflect real-world evidence realities. Static models fail dynamic healthcare landscapes.

MarcusStatic models anchor evidence to clinical validity. Without that, value assessments become speculative. Evolution must build on scientific rigor, not abandon it.

SaraThe tension between rigor and relevance defines modern HTA. Companies must bridge both with evidence that satisfies regulatory demands while addressing unmet needs. That's the strategic imperative.

MarcusEvidence must anchor in clinical reality. Adaptability follows from robust foundations, not the reverse.

SaraBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.